We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Biomarker Blocks Repair and Contributes to Kidney Failure

By LabMedica International staff writers
Posted on 08 Nov 2011
In some kidney diseases, patients have high blood levels of a protein that blocks blood vessel repair and inhibiting the protein may reduce patients' risk of developing kidney failure. More...


Patients with an autoimmune kidney disorder called anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis produce antibodies that damage blood vessels in the kidneys and these antibodies can be measured in their sera.

At the Institute of Transplantation Urology Nephrology (Nantes, France) scientists examined the blood of 81 patients with ANCA-associated vasculitis, 21 patients with other types of kidney disease, and 18 healthy individuals.

They measured the amount of the protein soluble vascular endothelial growth factor receptor 1 (Flt1) in the serum. Circulating Flt1 and complement component 5 (C5a) were assayed using commercial enzyme-linked immunosorbent assay (ELISA) kits.

The investigators found that compared with others in the study, patients with ANCA-associated vasculitis harbor elevated blood levels of the molecule Flt1, which hinders the repair of blood vessels. As a result, their bodies may not be able to fix damaged blood vessels, setting them on a path of continued disease progression. The ELISA kits used are products of R&D Systems (Minneapolis, MN, USA).

Serum levels of soluble Flt1 correlated with C5a, an anaphylatoxin released after complement activation. Serum from patients with acute ANCA-associated vasculitis disrupted blood flow in the chicken chorioallantoic membrane assay, suggesting an antiangiogenic effect. Preincubation with excess human vascular endothelial growth factor prevented this effect. Anti-proteinase-3 (PR3) monoclonal and serum containing PR3-ANCA from patients with active vasculitis both induced a significant and sustained release of soluble Flt1 from monocytes, whereas anti-myeloperoxidase (MPO) monoclonal or polyclonal antibodies did not.

Fadi Fakhouri, MD, PhD, the lead author of the study said, "Our data suggest that in some kidney diseases, not only are blood vessels damaged, but their repair is also impaired by an increase of Flt1 in the blood. Inhibiting Flt1 may help improve blood vessel repair in some kidney disease patients and thus reduce their risk of progression to kidney failure." The study was published on October 27 2011, in the Journal of the American Society Nephrology.

Related Links:
Institute of Transplantation Urology Nephrology
R&D Systems



New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
New
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.